Free Trial
→ Federal Reserve Reveals Disturbing New Plan To Control Your Money (From Weiss Ratings) (Ad)tc pixel
OTCMKTS:PURE

PURE Bioscience Q4 2025 Earnings Results & Report

PURE Bioscience logo
$0.07 +0.00 (+5.87%)
As of 03:58 PM Eastern

PURE Bioscience reported Q4 2025 earnings on October 29, 2025. The company reported EPS of -$0.01, while revenue was $1.71 million.

Research:ProfileEarnings History

Earnings Announcement Details

Quarter
Q4 2025
Report Date
Time
After Market Closes

PURE Bioscience EPS Results

Actual EPS
-$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

PURE Bioscience Revenue Results

Actual Revenue
$1.71 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

PURE Bioscience Q4 2025 Earnings FAQ

PURE Bioscience (OTCMKTS:PURE) reported earnings of -$0.01 per share for Q4 2025. The report was announced on Wednesday, October 29, 2025.

PURE Bioscience reported revenue of $1.71 million for Q4 2025.

PURE Bioscience Earnings Headlines

PURE Bioscience (OTCMKTS:PURE) Shares Cross Above Two Hundred Day Moving Average - Here's What Happened
October 14 at 3:01 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31117663
PURE Bioscience (OTCMKTS:PURE) Share Price Breaks Above 200-Day Moving Average - Time to Sell?
October 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31090260
Undiscovered Sub-$1 Gold-Silver Royalty Stock Takes Flight
A small-cap gold and silver royalty company is generating record revenue from producing mines, yet shares still trade under 1 dollar. It just signed the largest transaction in its history, a new gold streaming deal backed by a strategic relationship with a major mining investment firm. A well-known sector financier has invested his own money and joins the CEO in an exclusive interview breaking down the full story.tc pixel
October 16 at 1:00 AM  |  Digest Publishing (Ad)
Pure Bioscience Inc.
August 12, 2026  |  marketwatch.comhttps://www.marketwatch.com/investing/stock/pure/financials
PURE Bioscience Reports Fiscal Third Quarter 2026 Financial Results
June 15, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260615772156/en/pure-bioscience-reports-fiscal-third-quarter-2026-financial-results/
Purecore Strengthens Technical Advisory Expertise with Nuclear Fuel Cycle and Uranium Enrichment Specialist, Ted Rygas, PhD
June 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/15/3311870/0/en/purecore-strengthens-technical-advisory-expertise-with-nuclear-fuel-cycle-and-uranium-enrichment-specialist-ted-rygas-phd.html
See More PURE Bioscience Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PURE Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PURE Bioscience and other key companies, straight to your email.

About PURE Bioscience

PURE Bioscience (OTCMKTS:PURE), Inc. develops and commercializes antimicrobial products based on its proprietary silver dihydrogen citrate (SDC) technology. SDC is designed to provide broad-spectrum antimicrobial activity while serving as the active ingredient in disinfecting, sanitizing, and hygiene formulations.

The company’s product portfolio has included PURE-branded solutions for hard-surface disinfection and sanitation, as well as applications in food safety, commercial and industrial settings, healthcare, and other environments where microbial control is important. Its products are intended for use on surfaces, equipment, and other areas requiring cleaning and antimicrobial protection.

PURE Bioscience has historically marketed its products in the United States and has pursued additional commercial opportunities through distributors and strategic partners. The company is headquartered in California. Information about its current leadership and geographic operations is limited and may change over time.

View PURE Bioscience Profile
Earnings Tools